PatientsVille.com Logo


Revlimid Medical Research Studies

Up-to-date List of Revlimid Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Revlimid Medical Research Studies

Rank Status Study
1 Recruiting Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, prednisone;   Drug: lenalidomide, endoxan, prednisone
Outcome Measures: Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior Revlimid Treatment (REPEAT);   phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior Revlimid Treatment (REPEAT);   phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior Revlimid Treatment (REPEAT)
2 Recruiting A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age
Conditions: Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent;   Drug: Lenalidomide - single agent;   Drug: Lenalidomide in combination with azacitidine
Outcome Measures: Survival;   Remission Rate;   Remission Duration;   Cytogenetic Complete Remission Rate;   Overall Response Rate;   Progression-free survival;   Event-free survival;   Relapse-free survival;   30-day treatment-related mortality;   Safety and Tolerability
3 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
Outcome Measures: Progression free survival (PFS) for Follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL);   Adverse Events;   Complete response rate;   Overall response rate;   Duration of response;   Duration of complete response;   Time to the next anti-lymphoma treatment;   Time to treatment failure;   Time to histological transformation
4 Recruiting Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: All-Trans Retinoic Acid (ATRA)
Outcome Measures: Maximum Tolerated Dose (MTD) of Lenalidomide/Dexamethasone and All-Trans Retinoic Acid (ATRA);   Objective Response
5 Not yet recruiting Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Condition: Multiple Myeloma
Intervention: Drug: Revlimid (lenalidomide)
Outcome Measures: Progression Free Survival (PFS);   Response Rates;   Overall Survival (OS);   Time to Response (TTR) and Duration of Response (DOR);   Duration of Treatment with Revlimid;   Safety Profile of Revlimid
6 Recruiting Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
Outcome Measures: Type, frequency, severity and timing of adverse events and their relationship to combination therapy with lenalidomide plus dexamethasone.;   Duration of M-Protein response during combination therapy with Lenalidomide plus dexamethasone;   Confirmed M-Protein response;   Expression of angiogenic factors, cytokines, adhesion molecules, and myeloma biomarker expression
7 Not yet recruiting Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Conditions: Multiple Myeloma;   Neoplasms;   Plasma Cells;   Paraproteinemias;   Blood Protein Disorders;   Hematologic Diseases;   Therapeutic Uses
Intervention: Drug: Lenalidomide
Outcome Measures: Progression free survival (PFS);   Response Rate;   Time to progression (TTP);   Overall survival (OS);   Safety
8 Recruiting Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Revlimid
Outcome Measures: Duration of complete or near complete response w/ Revlimid therapy compared to group with no Revlimid therapy;   Toxicities associated with Revlimid versus no further Revlimid treatment
9 Unknown  Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL;   Untreated;   Front-line;   First-Line;   Initial Therapy
Intervention: Drug: Lenalidomide and Rituximab
Outcome Measures: Efficacy to be assessed by clinical response rate following 3 cycles of treatment and the NCI-CLL working group response rate assessed after completion of all treatment.;   Safety - type, frequency, severity, and relationship of adverse events to study treatment;   Time To Progression;   Evaluate response to lenalidomide in relationship to molecular and genetic prognostic features in CLL; including ZAP-70 status, IgVH gene mutational status, and FISH.;   Compare the efficacy and tolerability of the combination of Revlimid and rituximab for patients younger than 65 years, and for those 65 and older. •;   Evaluate change in hematological parameters including neutropenia, anemia, and thrombocytopenia following treatment with the combination of Revlimid and rituximab.
10 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
Outcome Measures: Overall survival;   Progression-free survival;   Response;   Toxicity
11 Unknown  Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL
Interventions: Drug: Revlimid, rituximab;   Drug: Relapsed or refractory CLL. Lenalidomide and Rituximab
Outcome Measures: iwCLL working group response rate assessed after completion of 7 cycles of treatment.;   adverse events to study treatment;   progression free survival.;   Conversion of MRD-positive complete response or partial response (PR) to a MRD-negative complete response (CR) or complete response (CR) respectively following an additional 6 cycles of Revlimid consolidation;   changes in hematological parameters;   Overall response in relationship to molecular and genetic prognostic factors;   Chronic Lymphocytic Leukemia up-regulated protein 1 (CLLU1);   overall survival.;   treatment free survival.
12 Recruiting Ipilimumab and Lenalidomide in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Ipilimumab;   Drug: Lenalidomide
Outcome Measures: Maximum Tolerated Dose (MTD) of Ipilimumab in Combination With Lenalidomide;   Dose-Limiting Toxicities (DLT) of Ipilimumab in Combination With Lenalidomide
13 Recruiting Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: nab-paclitaxel
Outcome Measures: maximum tolerated dose (Phase I);   the number of patients who achieve Complete Response (CR) or Partial Response (PR) (Phase II)
14 Recruiting Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy
Condition: Multiple Myeloma
Interventions: Drug: Nelfinavir;   Drug: Lenalidomide;   Drug: Dexamethasone
Outcome Measures: Phase I: Dose limiting toxicity;   Phase II: Overall response;   Phase I/II: Frequency and percent of occurrence of adverse events during each cycle of treatment, and within patients;   Phase I/II: Disease control, i.e. no progression at 16 weeks after start of trial therapy;   Phase I/II: Duration of response;   Phase I/II: Overall survival;   Phase I/II: Progression free survival;   Phase I/II: Time to progression;   Phase I: Overall response
15 Recruiting Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: Dexamethasone;   Drug: Clarithromycin;   Drug: Lenalidomide
Outcome Measures: Response to Car-BiRD treatment.;   Event free survival
16 Recruiting Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Lenalidomide; Chlorambucil
Outcome Measures: PhI: MTD of Lenalidomide given in combination with Chlorambucil.;   PhII: To evaluate the overall response rate of an induction therapy consisting of Lenalidomide given at the MTD in combination with Chlorambucil.;   Lenalidomide and chlorambucil induction therapy in terms of safety;;   Post-remissional phase with Lenalidomide in terms of safety;   Lenalidomide maintenance efficacy in terms of CR rate.;   Progression free survival estimation according to the post-remissional approach. lenalidomide maintenance therapy or clinical observation.;   Association between the response and the baseline biologic factors (IgVH, p53, FISH, ZAP-70, CD38);   Progression free survival estimation according to the baseline biologic factors starting from the date of first dose of study drug in the induction phase.;   Time to a new CLL treatment or death estimation.;   Overall survival estimation
17 Recruiting A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat;   Drug: lenalidomide
Outcome Measures: Determine the overall response rate (ORR), including complete responses (CR) and partial responses (PR), with combined lenalidomide and panobinostat in patients with relapsed or refractory Hodgkin's lymphoma.;   Assess the safety and tolerability of combined lenalidomide and panobinostat in patients with previously treated Hodgkin's lymphoma.;   Determine progression-free survival in patients with previously treated Hodgkin's lymphoma receiving combined lenalidomide and panobinostat
18 Recruiting Study of Revlimid (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Other: Placebo
Outcome Measures: Period until the progression of myelodysplastic syndrome;   Safety;   Erythroid response;   Duration of the red blood cells transfusion independency;   Change of the hemoglobin concentration (Hb) in relation to baseline levels;   Variation in platelets and neutrophils absolute count in relation to baseline levels;   Cytogenetic response;   Bone marrow response;   Global survival, Event Free Survival and Rate of Transformation to Acute Leukemia.;   Time from diagnose to transfusion independence.
19 Unknown  Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Conditions: Leukemia, Lymphoid;   Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Lenalidomide plus dexamethasone
Outcome Measures: Disease-Free survival (DFS);   Time to response;   Duration of response;   To determine quality of life (QOL): European Organization for Research and Treatment of Cancer QOL questionnaire for patients with cancer (EORTC QLQ-C30);   Progression-free survival;   Feasibility of stem cell transplantation (SCT), in case of response, after one or more cycles of lenalidomide plus dexamethasone therapy;   Safety of lenalidomide plus dexamethasone: adverse events (type, frequency, severity of adverse events, and relationship of adverse events to study drug).;   To assess the efficacy of lenalidomide plus low-dose dexamethasone: complete response (CR), complete response without platelets (CRp), partial response (PR), and overall response (CR + CRp + PR).;   Overall survival
20 Recruiting Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
Outcome Measures: overall response rate (ORR);   toxicity

These studies may lead to new treatments and are adding insight into Revlimid etiology and treatment.

A major focus of Revlimid research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Revlimid